Related Experiment Video
Updated: Jun 28, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
[Gastrointestinal stromal tumors. An update]
Pablo Bórquez Ma1, Rodrigo Neveu C
1Instituto Nacional del Cancer. tellomora@yahoo.es
Abstract:
Gastrointestinal stromal tumors (GIS) are a heterogeneous group of tumors that express CD 117 molecule in their sur face. They may behave as benign tumors or be highly aggressive. A better survival of patients with these tumors has been achieved using the new molecular therapies such as imatinib mesylate, sunitinib and others. This review analyzes the prognostic factors of these tumors, their clinical features and the criteria for malignant behavior. The value of therapeutic alternatives such as radiotherapy chemotherapy and the new molecular therapies are also discussed.
Insights
Gastrointestinal stromal tumors (GIS) are CD 117-positive tumors with variable behavior. Molecular therapies like imatinib have improved survival, and this review covers prognostic factors and treatment options.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Gastrointestinal stromal tumors (GIS) are a heterogeneous group of neoplasms expressing CD 117.
- These tumors can range from benign to highly aggressive, impacting patient prognosis.
- Recent advancements in molecular therapies have significantly improved survival rates for patients with GIS.
Purpose of the Study:
- To analyze prognostic factors and clinical features of GIS.
- To define criteria for identifying malignant behavior in GIS.
- To discuss the efficacy of various therapeutic alternatives, including molecular therapies.
Main Methods:
- Review of existing literature on GIS.
- Analysis of prognostic indicators and clinical presentation.
- Evaluation of therapeutic strategies: radiotherapy, chemotherapy, and molecular targeted therapies.
Main Results:
- Identification of key prognostic factors influencing GIS behavior.
- Established criteria for assessing the malignant potential of GIS.
- Demonstrated improved patient survival with targeted molecular therapies.
Conclusions:
- Understanding prognostic factors is crucial for managing GIS.
- Molecular therapies represent a significant advancement in GIS treatment.
- A comprehensive approach considering clinical features and therapeutic options is essential for optimal patient outcomes.
Related Concept Videos
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
The Tumor Microenvironment
